(19)
(11) EP 0 862 445 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
25.09.2013 Bulletin 2013/39

(45) Mention of the grant of the patent:
08.05.2013 Bulletin 2013/19

(21) Application number: 96934086.8

(22) Date of filing: 07.10.1996
(51) International Patent Classification (IPC): 
A61K 35/76(2006.01)
A61P 35/00(2006.01)
 A61K 45/06(2006.01)
A61K 48/00(2006.01)
(86) International application number:
PCT/US1996/016047
(87) International publication number:
WO 1997/012623 (10.04.1997 Gazette 1997/16)

(54)

Combination of herpes simplex virus and chemotherapy for treating cancer

Kombination von Herpes simplex Virus und Chemotherapie für Krebstherapie

Combinaison de virus herpes simplex avec la chimithérapie pour le traitement du cancer

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 06.10.1995 US 540343

(43) Date of publication of application:
09.09.1998 Bulletin 1998/37

(73) Proprietors:
  • Arch Development Corporation
    Chicago, IL 60637 (US)
  • DANA-FARBER CANCER INSTITUTE
    Boston, MA 02115 (US)

(72) Inventors:
  • HALLAHAN, Dennis, E.
    Park Ridge, IL 60068 (US)
  • WEICHSELBAUM, Ralph, R.
    Chicago, IL 60614 (US)
  • KUFE, Donald
    Wellesley, MA 02181 (US)
  • SIBLEY, Gregory, S.
    Chapel Hill, NC (US)
  • ROIZMAN, Bernard
    Chicago, IL 60637 (US)

(74) Representative: Bösl, Raphael Konrad et al
Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstrasse 68
81675 München
81675 München (DE)


(56) References cited: : 
EP-A1- 0 514 603
 WO-A2-95/20960
   
  • CANCER RESEARCH, vol. 54, no. 9, 1 May 1994, BALTIMORE, MD, US, pages 2287-2291, XP002025050 T. FUJIWARA ET AL.: "INDUCTION OF CHEMOSENSITIVITY IN HUMAN LUNG CANCER CELLS IN VIVO BY ADENOVIRUS-MEDIATED TRANSFER OF THE WILD-TYPE p53 GENE."
  • NATURE MEDICINE, vol. 1, no. 8, August 1995, NEW YORK, N.Y., US, pages 786-791, XP002024926 D.E. HALLAHAN ET AL.: "SPATIAL AND TEMPORAL CONTROL OF GENE THERAPY USING IONIZING RADIATION." cited in the application
  • JOURNAL OF VIROLOGY, vol. 68, no. 12, December 1994, WASHINGTON, DC, US, pages 8304-8311, XP002024927 J. CHOU ET AL.: "DIFFERENTIAL RESPONSE OF HUMAN CELLS TO DELETIONS AND STOP CODONS IN THE GAMMA 1 34.5 GENE OF HERPES SIMPLEX VIRUS." cited in the application
  • INTERNATIONAL JOURNAL OF CANCER, vol. 67, no. 3, 29 July 1996, GENEVA, CH, pages 386-392, XP000644437 M.V. BLAGOSKLONNY ET AL.: "IN VITRO EVALUATION OF A p53-EXPRESSING ADENOVIRUS AS AN ANTI-CANCER DRUG."
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).